GSK grabs an option to Five Prime therapies; Annalisa Jenkins tapped as new CEO of Dimension Therapeutics; AstraZeneca opens a big new IT center in India;

@FierceBiotech: Lilly takes the lead on AstraZeneca's Alzheimer's drug in $500M deal. News | Follow @FierceBiotech

@JohnCFierce: Biotech R&D is changing. Don't get left behind. (A shameless plug for upcoming executive breakfast panel in Boston). More | Follow @JohnCFierce

@DamianFierce: Oxygen Bio will soon be Tenax Therapeutics. Release | Follow @DamianFierce

@EmilyMFierce: Great piece on the trials and tribulations of stem cell research. Report from the NYT | Follow @EmilyMFierce

> GlaxoSmithKline ($GSK) has taken an option on the muscle disease drugs developed at South San Francisco-based Five Prime. The deal dates back 4 years. Five Prime gets a payment of $1.5 million in connection with the option exercise and up to $122.5 million in preclinical, development and commercial-related milestone payments and royalties in the low- to mid-single-digit range on net sales of products related to the target. Release

> Cambridge, MA-based Dimension Therapeutics, a gene therapy upstart, named Annalisa Jenkins as its new CEO. Jenkins recently wrapped a stint as head of R&D at Merck KGaA and earlier worked for Bristol-Myers Squibb ($BMY). Release

> AstraZeneca ($AZN) has opened up a new Global Technology Centre to build up its IT infrastructure. The center plans to have a staff of 300 by the end of this year. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Danaher cements commitment to dental with $2.2B Nobel acquisition. Article | Follow @FierceMedDev

@MichaelGFierce:  Liposome research adds up to better #cancer treatment options. More | Follow @MichaelGFierce

> WSJ: What are the costs and benefits of early cancer screening? Item

> Harvard researchers develop dialysis device to fight Ebola. Story

> Former Alere execs assemble $3.8B take-private offer. Report

Pharma News

@FiercePharma: Top-read in FierceAnimalHealth Mon: FDA seeks input on conditional approvals for new animal health products. Story | Follow @FiercePharma

@EricPFierce: Merck KGaA turns to India's Lupin to manufacture $2B worth of drugs in emerging markets. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Would Ian Read keep his AZ deal promises? U.K. panel eyes new rules to enforce them. ICYMI yesterday | Follow @CarlyHFierce

> Switzerland wants to slash drug prices? Not so fast, say Novartis and Roche. More

> Allergan, Valeant agree on meeting date. Now, the fight for shareholder votes. Story

> NY sues Actavis and Forest for 'monopoly' on Alzheimer's drug. Report

Biotech Research News

> Notable academic-pharma alliances of 2014. Feature

> Geneva Foundation gets $3M NIH grant for Ebola drug work. News

> Protein stops bone loss in arthritic mice. More

> Google's Calico acquires UT Southwestern compounds for neurodegenerative disorders. Story

> $64M NIH initiative will catalog cell responses to drugs. Article

Pharma Manufacturing News

> Gilead hands Sovaldi manufacturing tech to 7 generics makers. Report

> Merck negotiates huge production deal with Lupin. More

> Hikma opens oncology API plant in Jordan. Article

> India's top drugmakers forecast to invest $8B in production upgrades. Item

> Hospira again reports a human hair discovered in a product. Story